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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the leading causes 
of human infections worldwide, with major dominant lineage circulating in particular 
geographical regions. The Brazilian Epidemic Clone (BEC, SCCmec III, ST 239) has been 
predominant in most Brazilian hospitals. Here, we report the prevalence of MRSA SCCmec 
type II exhibiting different STs, most of them belonging to CC5 in a tertiary hospital in 
Southern Brazil.
KEYWORDS: MRSA. Multi-drug resistance. PVL. Toxic shock syndrome toxin. 
Methicillin-resistant Staphylococcus aureus.
Staphylococcus aureus can asymptomatically colonize various human body 
sites. However, it is also an important human pathogen that causes a wide diversity 
of infections, ranging from minor skin and soft tissue infection to life-threatening 
conditions. This bacterium has developed numerous mechanisms of antimicrobial 
resistance, limiting the treatment options for staphylococcal infections1. The 
acquisition of the staphylococcal cassette chromosome mec (SCCmec), carrying 
the mec (A or C) genes and the site-specific cassette chromosome recombinase (ccr) 
genes (ccrAB or/and ccrC), plays a pivotal role in the antimicrobial resistance of S. 
aureus. The mec genes encode a specific penicillin-binding protein (PBP2a or PBP2’) 
with significantly lower affinity to β-lactams. In addition, multiple antibacterial-
resistant and heavy metal-resistant encoding genes can be inserted into this cassette 
by site-specific recombination1.
Currently, methicillin-resistant S. aureus (MRSA) is responsible for a high 
proportion of staphylococcal infections in both community and hospital settings2. 
Particularly in Latin America, MRSA is highly prevalent in hospitals and circulating 
MRSA clones can vary according to the geographic regions2. Remarkably, the 
Brazilian Epidemic Clone (BEC, ST 239, SCCmec III), first detected in Brazil in 
the 1990s3, has been predominant in most Brazilian hospitals4. However, changes 
in the population structure of MRSA have also been reported in some hospitals 
in this country. Caiaffa-Filho et al.5 reported the prevalence of MRSAs harboring 
SCCmec type II in a hospital of Sao Paulo. The USA800/ Pediatric (ST5, SCCmec 
IV) and USA400/ MW2/WA-1 (ST1, SCCmec IV) were the most predominant 
MRSA lineages in five hospitals of Rio de Janeiro6. On the other hand, the USA100 
(formerly designated as New York/Japan clone/ST5/ CC5/ SCCmec II) associated 
with multidrug resistance was the predominant MRSA lineage in a military hospital, 
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whereas polyclonal and non-multidrug resistant MRSA 
isolates were detected in a teaching hospital of Rio de 
Janeiro7. Arias et al.2 reported prevalence higher than 80% 
of USA100 in three Brazilian hospitals located in the cities 
of Sao Paulo and Porto Alegre.
The University Hospital of Londrina (UHL) is a 
teaching hospital and a major referral center in the North 
of Parana State, Brazil, for the Sistema Unico de Saude 
(SUS), a governmental public health system. This is a 313-
bed tertiary care center that serves the city of Londrina, 
besides about 250 localities of Parana State and more than 
100 cities from other States, mainly in Sao Paulo, Mato 
Grosso, Mato Grosso do Sul and Rondonia. The number of 
MRSA isolates detected in this hospital has increased over 
the years. Here, we report the prevalence of MRSA CC5/ 
SCCmec II in the UHL. 
A total of 59 non-duplicate MRSAs isolated from 
inpatients with diagnosis of bloodstream and respiratory 
tract infections during 2015-2016 were taken from the 
bacterial collection of the Clinical Microbiology Laboratory 
of UHL. 
Ethics Committee on Research Involving Human 
Beings of Universidade Estadual de Londrina (CAAE Nº 
78657317.0.0000.5231 CEP-UEL) approved the study 
protocols. The isolates were recovered from tracheal 
aspirates (n=44) and blood (n=15). Species identification 
was based on the phenotypic profile generated by the 
VITEK® 2 Compact using VITEK® 2 GP ID card and 
OBSERVA® Integrated Data Management software version 
04.03 (bioMérieux- Durham, NC, USA). At the same time, 
Gram staining, catalase, DNase and mannitol fermentation 
were also determined. Antimicrobial susceptibility for 
cefoxitin (30 µg), erythromycin (15 µg), clindamycin (2 µg), 
gentamicin (10 µg), ciprofloxacin (5 µg), sulfamethoxazole-
trimethoprim (23.75/1.25 µg), rifampicin (5 µg), linezolide 
(10 µg) and tigecycline (15 µg) was determined by disk 
diffusion assay according to Clinical Laboratory Standards 
Institute (CLSI)8. The susceptibility breakpoints used were 
those recommended by the CLSI8, except for tigecycline 
that was interpreted according to the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST)9. The 
minimum inhibitory concentration (MIC) of vancomycin 
was determined by Etest® (ABBiodisk, Solna, Sweden). 
Cefoxitin was used to define MRSA phenotypically8.
All isolates were susceptible to rifampicin, 
sulfamethoxazole-trimethoprim, linezolide and tigecycline. 
All isolates were resistant to oxacillin, erythromycin, 
clindamycin and ciprofloxacin, except one that exhibited 
resistance only to oxacillin. Resistance to gentamicin was 
detected in two isolates. The vancomycin MIC ranged from to 
0.5 to 2.0 µg/mL. The mechanism of methicillin resistance is 
mediated by the mecA gene for most isolates (52/59, 88.1%), 
as judged by the results of multiplex-PCR assay10. Seven 
(11.9%) isolates did not harbor the mecA gene. 
Besides the synthesis of modified PBP2a mediated by 
mecA gene, other mechanisms may be related to methicillin 
resistance in S. aureus: a) the presence of divergent mecA 
homologue known as mecC (formerly mecALGA251 gene) that 
was detected in MRSAs isolated from animals and humans1; 
b) the presence of a plasmid-encoded mecB gene that has 
recently been described in one MRSA recovered from 
surveillance cefoxitin-based nasal screening in a German 
hospital11; c) point mutations in genes encoding PBP 1, 2 and 
3, resulting in amino acid substitutions in the transpeptidase 
domains of these proteins12; d) hyperproduction of beta-
lactamase that partially hydrolyses penicillinase-resistant 
penicillin, such as methicillin13.
By using the multiplex-PCR described by Milheiriço 
et al.10, mecA harboring MRSA isolates (n=52) were 
distributed into four SCCmec types. Remarkably, the 
predominance of SCCmec type II (34/52, 65.4%) was 
observed among the MRSA isolates. Eight (15.4%) isolates 
each were classified as SCCmec type I and IV. One (1.9%) 
isolate harbored the SCCmec type III and one (1.9%) was 
untypeable. We used the High-Resolution Melting (HRM) 
analysis of Single Nucleotide Polymorphisms (SNPs), as 
described by Lilliebridge et al.14 to further investigate the 
clonal relatedness among SCCmec type II MRSAs. Twelve 
different sequence types (STs) were detected, which include 
ST5 (n=3), ST6 (n=2), ST9 (n=2), ST27 (n=2), ST53 (n=2), 
ST63 (n=7), ST99 (n=2), ST306 (n=3), ST445 (n=5), ST835 
(n=4), ST1307 (n=1) and ST1502 (n=1). Based on STs 
similarities, these MRSAs were clustered into five clonal 
complexes (CC) (Table 1). The majority of MRSA SCCmec 
II isolates belonged to CC5 (n=23, 67.6%), which has been 
commonly associated with human infections worldwide2,15.
Recent studies of our research group have reported the 
predominance of MRSA harboring SCCmec II elements 
isolated from different clinical sources in the UHL during 
2010 to 2013. Prevalences of 53.7% (66 out of 123 MRSAs 
isolates) and of 43.6% (24 out of 55 MRSAs isolates) 
were described by Oliveira et al.16 and Bodnar et al.17, 
respectively. In both studies, most isolates were also 
resistant to erythromycin, clindamycin and ciprofloxacin. 
In contrast to our results, both studies reported MRSA 
isolates showing intermediate resistance to vancomycin. 
Of note, there was a substantial proportion of MRSAs 
exhibiting MIC values equal or higher than 1.5 µg/mL for 
vancomycin. Although these isolates are reported to be 
susceptible, data from the literature suggest that patients 
with MRSA infections presenting these MIC values respond 
poorly to vancomycin1.
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We also investigated the presence of genes lukS-PV 
and lukF-PV and tst-1 in SCCmec type II MRSAs by PCR 
as described previously15. Seven SCCmec type II isolates 
(20.6%) harbored the PVL-encoding genes, which contrast 
with the results of de Oliveira et al.15 that detected these 
genes only in MRSA SCCmec type IV (3/123, 2.4%). The 
lukS-PV and lukF-PV encode the β-pore-forming cytotoxic 
Panton-Valentine leukocidin (PVL), a secreted toxin that 
has been associated with S. aureus skin and soft tissue 
infections, necrotizing pneumonia and septic shock. These 
genes are encoded by bacteriophages, which can contribute 
for their dissemination among MRSA strains18. In contrast, 
none MRSA SCCmec type II harbored the tst-1 gene in 
this study, whereas this gene was detected in 5.7% (7 out 
Table 1 - Molecular characteristics and antimicrobial susceptibility profile of 34 methicillin-resistant Staphylococcus aureus SCCmec 
type II isolated in 2015-2016 
Isolate CCa STa PVLb tst-1b Antibiotypec Yeard Sourcee Vancomycin µg/mLg
110 7 306 - - II 2015 T 1.5
138 5 835 + - II 2015 T 2.0
160 7 306 + - II 2015 T 1.5
165 5 63 + - II 2015 T 1.5
175 80 1502 - - II 2015 T 2.0
176 5 835 + - II 2015 T 2.0
177 5 63 - - II 2015 T 1.5
185 5 63 - - II 2015 T 1.5
193 5 63 - - II 2015 B 2.0
209 5 5 - - II 2015 T 1.5
211 5 835 + - I 2015 B 1.5
215 5 63 - - II 2015 B 2.0
219 5 63 - - II 2015 T 1.5
265 7 306 - - II 2015 T 2.0
332 5 835 + - II 2015 T 2.0
352 5 6 - - II 2015 T 1.5
353 5 27 - - II 2015 T 1.5
356 5 9 - - II 2015 T 2.0
369 5 27 - - II 2015 T 1.5
374 5 9 + - II 2015 B 1.5
411 5 6 - - II 2015 T 2.0
413 5 99 - - II 2015 T 1.5
415 5 5 - - II 2015 B 1.5
419 5 63 - - II 2015 T 1.5
437 5 5 - - II 2015 T 2.0
453 5 1307 - - II 2016 T 2.0
465 1290 53 - - III 2016 T 1.0
483 445 445 - - II 2016 T 2.0
484 1290 53 - - II 2016 B 2.0
492 445 445 - - II 2016 T 2.0
577 445 445 - - II 2016 T 1.5
578 445 445 - - II 2016 T 1.5
631 5 99 - - II 2016 B 2.0
657 445 445 - - II 2016 T 1.5
aCC: Clonal Complex and ST: Sequence Typing were determined as described by Lilliebridge et al.14; bPVL: Panton Valentine 
Leukocidin encoding gene and tst-1: Toxic Shock Syndrome Toxin encoding gene were detected as described in Oliveira et al.16; 
cAntimicrobial resistance profile was determined by disk-diffusion assay according to the CLSI guidelines8- I: OXA; II: OXA, ERI, 
CLI, CIP; III: OXA, ERI, CLI, CIP, GN; OXA: Oxacillin, CLI: Clindamycin, ERI: Erithromycin, CIP: Ciprofloxacin; GN: Gentamicin; dYear 
of isolation; eSource of isolation, T: Tracheal secretion, B: Blood; fMIC vancomycin determined by E-test; - Absence; + Presence.
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of 123) of MRSA harboring the same SCCmec elements 
in our previous study16. The tst-1 gene encodes the toxic 
shock syndrome toxin (TSST-1), a member of bacterial 
superantigen family, which induces a massive activation 
of monocytes/macrophages and T lymphocyte host cells, 
leading to a potentially fatal toxic shock syndrome. This 
gene is located in a mobile pathogenicity island which uses 
bacteriophage-mediated transfer for its mobilization19. The 
contribution of a horizontal gene transfer for the bacterial 
adaptation in a determined niche has been well-studied. 
However, the role of gene loss in bacterial fitness has 
received less attention, thus further studies are needed to 
understand this phenomenon.
The relatively small number of isolates, the samples 
origin (tracheal aspirates and blood) and detection of two 
virulence-encoding genes by PCR are the limitations of 
our study, which may reduce the generalization of results. 
Nevertheless, this study reports the predominance of MRSA 
SCCmec type II exhibiting different STs, most of which 
belong to CC5 in UHL. The SCCmec type II remained 
relatively stable over the five years period studied by 
our research group; however, an increase in the presence 
of PVL- and the absence of TSST-encoding genes were 
detected among these strains. Due to the mobility of MGEs, 
new patterns of antibiotic resistance and virulence can 
emerge, and then continuous surveillance of S. aureus and 
of these traits are crucial for the development of preventive 
and therapeutic approaches for the treatment of infections 
caused by this bacterium. Corroborating this, a recent 
study of Wang et al.15 showed that CC5 isolates, SCCmec 
type II and erythromycin resistance are independent risk 
factor associated with 30-day mortality of patients with 
MRSA infections. In addition, a higher risk of death 
has been reported in patients with pneumonia caused by 
PVL-positive S. aureus, compared to non-PVL producing 
isolates20.
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